Menu
Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1
Cytotoxic effects of curcumin in osteosarcoma cells
Authors Moran J, Rodriguez-Velasco FJ, Roncero-Martin R, Vera V, Pedrera-Zamorano JD
Received 26 September 2014
Accepted for publication 4 October 2014
Published 14 November 2014 Volume 2014:9(1) Pages 5273—5275
DOI https://doi.org/10.2147/IJN.S75005
Checked for plagiarism Yes
Editor who approved publication: Prof. Dr. Thomas J Webster
JM Moran, FJ Rodriguez-Velasco, R Roncero-Martin, V Vera, JD Pedrera-Zamorano
Metabolic Bone Diseases Research Group, University of Extremadura, Cáceres, Spain
We read with interest the results of the study from Chang et al1 in the International Journal of Nanomedicine. This article shows that curcumin (diferuloymethane), a phenolic compound extracted from the natural plant Curcuma longa L., exerts higher cytotoxicity in osteosarcoma MG-63 cells than in healthy human osteoblasts. Based on the dosages provided by the authors it is hypothesized that with the appropriate drug carriers, curcumin could be delivered to bone tumors and selectively kill osteosarcoma cells without harming healthy osteoblasts. This hypothesis is based in the data provided that claims the dose needed to exert a significant cytotoxicity on osteosarcoma cells was much lower than that needed to exert the same effect on healthy human osteoblasts. The topic of this study is of importance for both cancer and metabolic bone disease fields, we appreciate the methodology of the study, nevertheless we believe that the hypothesis formulated by the authors and their conclusion deserves further comment.
View original paper by Chang and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.